Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prevnar 20 Safety and Immunogenicity in Healthy Infants (3-Dose Series)
NCT04546425Phase 3Completed
- Sponsor
- Pfizer
- Start
- Sep 2020
- Primary completion
- Apr 2022
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 12
01
Overview
Phase 3, randomised, double-blind trial of Prevnar 20 in pneumococcal disease (2 arms), sponsored by Pfizer. Primary endpoints: Percentage of Participants With Local Reactions Within 7 Days After Each Dose, Percentage of Participants With Systemic Events Within 7 Days After Each Dose and 7 more. Started Sep 2020; status: completed.
02
Drugs
Prevnar 20
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on NCT04546425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04546425.